Cell and Gene Therapy
Leading the way in precision targeting and therapeutic innovation
The remarkable advancements in cell and gene therapy are unlocking new possibilities for the next generation of targeted treatments. As research evolves, there is a growing focus on two main approaches: in vivo gene therapy, which involves delivering therapeutic genes directly into the body to correct monogenic aberrations, and ex vivo gene therapy, where cells are modified outside the body and then reinfused to harness the immune system or repair defective genes. Additionally, cell therapy continues to drive innovations by leveraging cellular-level interventions to treat and cure diseases.
Our integrated workflows are designed to support precise gene editing, accurate cell analysis, and optimized AAV and lentiviral vector development, providing comprehensive solutions at every critical stage of in vivo and ex vivo gene therapy. We offer innovative tools and expertise in gene delivery, therapeutic optimization, and scalable manufacturing to enhance the specificity, safety, and efficacy of your cell and gene therapies.
Key development stages:
- Discovery and lead identification: Target identification, biological mechanism validation, and gene editing
- Therapeutic payload and delivery: Payload design, vector development, and CAR-T cell therapy solutions
- Pre-clinical development: Cell characterization, organoid development, bioanalytical assays, and high-content imaging
- Scale-up and manufacturing: Integrated automation systems, vector scale-up, and GMP-grade reagents
- Quality assurance and control: Nucleic acid isolations, AlphaLISA™ AAV detection kits, and LabChip™ AAV empty/full characterization
Explore how our integrated solutions can help you advance your cell and gene therapy projects from discovery to commercialization.
For research use only. Not for use in diagnostic procedures.
